Five Questions to Ask Before Entering the Canadian Diagnostics Market

Most US diagnostics companies do not make a deliberate decision to enter Canada. Canada appears on the expansion slide because it is geographically adjacent, English-speaking, and assumed to be a simpler version of the US market. That assumption is the first capital misallocation.

The best-case scenario for reaching public reimbursement in even one Canadian province covering 20% of the population is approximately 534 days from market authorization—nearly double the OECD median. For country-wide coverage reaching 80% of the population, the timeline is significantly longer. Many specialized genomic tests never reach it at all. Only about 39% of new medicines and their associated diagnostics achieve country-wide public reimbursement in Canada, compared to nearly 100% in median OECD comparator countries. For orphan indications and rare oncology variants, that figure drops to 29%.

These are not operational delays. They are structural features of a system where Health Canada approval is a licence to sell, not a guarantee that anyone is permitted to buy. The question is not whether your test can enter Canada. It is whether you have budgeted 18 to 24 months of unfunded clinical activity, evidence generation, and provincial engagement before the first reimbursed sample arrives.

If Canada is not explicitly sequenced in your launch plan with that timeline and capital reserve, it is not a strategic target. It is a hope.

A significant portion of advanced molecular testing in Canada is performed as Laboratory Developed Tests within large academic centres. These are not fringe operations. They are established programs at institutions with deep technical capability and constrained budgets. When a US company arrives with a premium-priced IVD kit or send-out service, the first question a Canadian lab director asks is not "how good is your test?" It is "can we do this ourselves?"

The answer depends entirely on what kind of test you are selling. For NGS panels on solid tumours or ctDNA assays, the vulnerability is real. Canadian academic labs can and do run comparable assays in-house. If your commercial panel does roughly what their LDT does, you are competing against a homebrew alternative with no kit cost and no margin for you. The competitive question is not analytic performance. It is whether the lab can achieve equivalent results at a fraction of the cost—and in many cases, it can.

But the dynamic inverts for tests that carry a deep clinical validation moat. Prognostic assays that require large-scale outcomes trial data—quality-of-life improvement, disease-free survival, chemotherapy benefit prediction—cannot be replicated by a local lab running a panel. The validation burden is too high and the regulatory requirements for a Health Canada-approved IVD kit create a barrier that a single-site LDT cannot clear. For these tests, labs are not reluctant buyers. They are willing adopters, because the alternative is not a cheaper LDT. The alternative is no test at all.

The question for your boardroom is: which category does your test fall into? If a Canadian academic lab can run a functionally equivalent assay on existing instrumentation, your commercial model must account for that competitive reality. If your test carries proprietary validation data that no LDT can reproduce, your Canadian path is fundamentally different—and often significantly easier.

For ultra-specialized tests not yet performed in Canada, provinces use out-of-country funding to send samples to US laboratories. This is a real revenue pathway and often the fastest route to initial Canadian volume. But it is not a business model. It is borrowed time.

Out-of-country funding is restrictive, case-by-case, and structurally designed to be temporary. Provinces have implemented reimbursement disincentives for US medical services and actively work to repatriate testing when local capacity becomes viable. When a province decides it can perform your test domestically—or a Canadian academic centre builds a comparable LDT—out-of-country funding can be redirected with little warning. There is no guaranteed transition period. The revenue stream you built your forecast on may not survive the shift.

The strategic question is what you are building during the out-of-country window. If you are shipping samples and collecting revenue without investing in a local partnership, you are building on ground you do not own. The companies that convert out-of-country access into sustainable Canadian presence are the ones that use the bridge period to establish collaborative relationships with Canadian labs—co-developing validation data, integrating bioinformatics workflows, or embedding their analytics layer into a local testing program.

Because here is the part most US companies underestimate: when repatriation happens, the wet-bench work is rarely the barrier. Any well-equipped Canadian lab can run the assay. What they cannot easily replicate is the bioinformatics pipeline—the variant calling, the data analytics, the software interpretation layer that turns raw sequencing data into a clinically actionable report. If your moat is in the informatics, build the partnership that protects it. If your moat is only in running the assay, repatriation is a question of when, not whether.

US companies routinely assume that FDA clearance and US-generated clinical data constitute a sufficient evidence package for Canadian market entry. They do not. Canadian payers operate with a distinct evidence hierarchy, and a dossier built exclusively for the US market will stall in Canadian review.

The first gap is economic modelling. Canadian economic evaluation guidelines prioritize the QALY framework, but for many genomic tests—particularly hereditary risk panels and pharmacogenomic assays—the value lies in what is increasingly called "personal utility": the benefit a patient derives from knowing their genetic status, even when it does not immediately alter clinical management. A cost-effectiveness model built around life years gained may be technically sound and still be judged insufficient by an HTA body that expects the patient utility dimension to be addressed.

The second gap is local validation. Canadian lab directors are deeply concerned with concordance—evidence that your test, performed in your US CLIA lab, produces results consistent with what a Canadian lab would generate using its own methods. Without concordance data, your test will be treated as unvalidated regardless of its FDA status. This is not a bureaucratic preference. It is a clinical governance requirement rooted in the principle that patient management decisions in Canadian institutions must be supported by locally verified evidence.

The third gap is real-world evidence. Canadian HTA bodies are increasingly using time-limited reimbursement models that grant provisional funding while requiring the manufacturer to collect Canadian-specific real-world data within defined timelines. Failure to deliver that data results in loss of funding. This is not optional post-market surveillance. It is a contractual condition of access. If your organization does not have the infrastructure to run a Canadian RWE collection program, your evidence package has an expiry date built into it.

The question for your team: can your evidence package address economic modelling in QALY terms with a patient utility dimension, provide concordance data against Canadian laboratory methods, and sustain a time-limited RWE collection mandate? If the answer to any of these is no, you are not ready to submit.

In the US, the oncologist is often the functional decision-maker for diagnostic adoption. The physician identifies the clinical need, the hospital system processes the order, and the payer adjudicates the claim. The commercial model is built around physician engagement, and the sales force is deployed accordingly.

In Canada, the oncologist identifies the need. But the oncologist does not control whether the test is performed. The molecular pathologist and the laboratory director are the functional gatekeepers. They determine whether a test is operationally viable within their lab infrastructure, whether results can be integrated into the provincial laboratory information system, whether the reporting format meets institutional standards, and whether the test fits within the laboratory's global budget.

If the pathologist decides your test is a resource drain—because results require manual data entry, because the reporting format does not match their LIS, because the turnaround time creates workflow disruption—the test does not get adopted. Clinical demand from oncologists is necessary. It is not sufficient.

Beyond the lab, the evolving HTA hierarchy adds another layer. Canada's Drug Agency is introducing standalone assessment reports for drugs that impact diagnostic testing resources, and expert advisory panels are setting guidelines on minimum retesting intervals that directly constrain how often monitoring assays can be ordered. These bodies set the rules of engagement for your test's market size, and most US companies do not know they exist until after their commercial plan is built.

The question: does your Canadian engagement plan include the molecular pathologist, the lab director, and the provincial policy bodies that govern test utilization? Or are you running a US commercial playbook that stops at the oncologist's office?

These five questions share a common thread: they test whether your organization has Canadian-specific structural literacy or is operating on US-derived assumptions. The companies that succeed in Canada are not the ones with the strongest science or the largest sales force. They are the ones that understood, before committing capital, that Canada requires a distinct commercial blueprint—different evidence, different stakeholders, different timelines, and a fundamentally different definition of market readiness.

If your team cannot answer these five questions with specificity—not in general terms, but province by province, pathway by pathway—then the Canadian expansion discussion is not ready for a budget line. It is ready for a structured diagnostic of what you do not yet know. That is the work we do at SignalPoint Access Intelligence.